Reduction in the relapse rate was as expected relatively weak but on efficacy Teva will emphasize the strong reduction in disability progression (measured by the EDSS scale) as only Avonex (not even Gilenya) among first line agents showed a slightly higher rate.
Market Data 
Markets 
AI
